- Home
- MSM vs KNSA Comparison
MSM vs KNSA Comparison
Compare MSM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSM | KNSA |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 4.9B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MSM | KNSA |
|---|---|---|
| Price | $125.92 | $62.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $96.20 | $60.86 |
| AVG Volume (30 Days) | 847.3K | ★ 905.3K |
| Earning Date | 04-01-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 3.12 | 0.27 |
| Revenue | ★ $3,363,817,000.00 | $677,564,000.00 |
| Revenue This Year | $5.82 | $37.48 |
| Revenue Next Year | $5.26 | $17.87 |
| P/E Ratio | ★ $40.33 | $233.52 |
| Revenue Growth | 4.99 | ★ 60.09 |
| 52 Week Low | $78.80 | $26.51 |
| 52 Week High | $128.79 | $67.53 |
Technical Indicators
Market Signals| Indicator | MSM | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 55.14 |
| Support Level | $82.07 | $60.07 |
| Resistance Level | $127.25 | $67.53 |
| Average True Range (ATR) | 2.93 | 2.60 |
| MACD | -0.04 | -0.45 |
| Stochastic Oscillator | 74.78 | 33.82 |
Price Performance
Historical ComparisonAbout MSM MSC Industrial Direct Company Inc.
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.